NIH-Funded Study Indicates ChromeMate® Reduces Vascular Inflammation
Back to Research
In a study funded by the National Institute of Diabetes and Digestive Kidney Diseases (NIDEDK), a division of the National Institutes of Health (NIH), ChromeMate® was found to prevent vascular inflammation, while chromium picolinate did not. Reduction of vascular inflammation can decrease the risk of cardiovascular disease, which is closely linked with diabetes. The eight-week study measured blood markers for vascular inflammation including TNF-α, MCP-1, retinol binding protein-4 (RBP-4), cholesterol and triglycerides in obese type 2 Zucker diabetic rats. The diets of test animals were supplemented with 400 mcg of chromium (III) from ChromeMate® or chromium picolinate per kilogram of body weight. When compared with animals in the control group, the ChromeMate® group exhibited significantly lower total cholesterol and triglycerides than the group supplemented with chromium picolinate. Levels of TNF-α, MCP-1, RBP-4 were also significantly lower in the ChromeMate® group than the control group, while the chromium picolinate group did not show any reduction in these marks.
Jain SK, Rains JL, Croad JL. Comparative efficacy chromium-niacinate and chromium-picolinate supplementation in the prevention of vascular inflammation in type 2 zucker diabetic rats.
Presented at the 68th Annual American Diabetic Association Scientific Sessions, June 2008, San Francisco, Calif.
Back to Research